MiMedx Group, Inc. (MDXG)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$3.28+2.50%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · MDXG
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
"We are working diligently with the FTC to obtain HSR clearance and look forward to completing the acquisition of Sanara MedTech.
Stated in 2 of 3 supplied quarters. Management reported: “Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "Our third quarter results reflect the progress we have made in reshaping MIMEDX into a Surgical-led company with a leaner cost structure that returned us to positive Adjusted EBITDA.” “"We are working diligently with the FTC to obtain HSR clearance and look forward to completing the acquisition of Sanara MedTech.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“"We are working diligently with the FTC to obtain HSR clearance and look forward to completing the acquisition of Sanara MedTech.”
“Additionally, with today’s announcement to acquire Sanara MedTech, we are accelerating our plan to create long-term success and shareholder value," concluded Mr. Capper.”
Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "Our third quarter results reflect the progress we have made in reshaping MIMEDX into a Surgical-led company with a leaner cost structure…
Stated in 3 of 3 supplied quarters. Management reported: “The $40 million in annualized savings we expect to generate from those actions will position us for a return to profitability over the balance of the year.” “Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "Our third quarter results reflect the progress we have made in reshaping MIMEDX into a Surgical-led company with a leaner cost structure that returned us to positive Adjusted EBITDA.” Operating income was $-11.702 million in 2026-Q3.
“Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "Our third quarter results reflect the progress we have made in reshaping MIMEDX into a Surgical-led company with a leaner cost structure…”
“"Early in the second quarter, we took swift action to right-size our expense structure for the current market environment, which yielded improving results throughout the quarter, putting us on a path…”
“The $40 million in annualized savings we expect to generate from those actions will position us for a return to profitability over the balance of the year.”
The Company expects Adjusted EBITDA for the fourth quarter to be sequentially higher than the third quarter.
Stated in 3 of 3 supplied quarters. Management reported: “Financial Outlook For 2026, MIMEDX now expects 2026 net sales to be in a range of $250 to $260 million.” “As a result of disruption in the wound care market, we are lowering full-year 2026 net sales expectations to a range of $260 to $290 million.” Net income was $-8.683 million in 2026-Q3.
“The Company expects Adjusted EBITDA for the fourth quarter to be sequentially higher than the third quarter.”
“2026 Adjusted EBITDA is expected to approach breakeven on a full year basis.”
“2026 Adjusted EBITDA is expected to be approximately breakeven on a full year basis.”
Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "Our third quarter results reflect the progress we have made in reshaping MIMEDX into a Surgical-led company with a leaner cost structure…
Stated in 2 of 3 supplied quarters. Management reported: “Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "Our third quarter results reflect the progress we have made in reshaping MIMEDX into a Surgical-led company with a leaner cost structure that returned us to positive Adjusted EBITDA.” “Our sustained momentum in several Surgical settings represents a meaningful, long-term growth opportunity for the Company, and we are focused on expanding into other procedures."”
“Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "Our third quarter results reflect the progress we have made in reshaping MIMEDX into a Surgical-led company with a leaner cost structure…”
“Our sustained momentum in several Surgical settings represents a meaningful, long-term growth opportunity for the Company, and we are focused on expanding into other procedures."”
Complete the merger with Sanara MedTech to nearly double surgical revenue and accelerate growth with over $20 million in run-rate cost synergies.
Over the trailing year it converted 20.70x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 54% of the time over the next year (vs 44% for the rest of the cohort, n=2525).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
7 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.